GlassScriptPhysician profile
Nathan Carberry
NPI 1083147839
$4,882.67
in general payments reported to CMS, 2019-2025
8 companies · $24.95 in 2025
The $24.95 reported for 2025 was less than what a typical Neuromuscular Medicine (Psychiatry & Neurology) provider received nationally (typical 2025 total: $530).
See the full distribution for Neuromuscular Medicine (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $35.20 · 2022: $370 · 2023: $4,453 · 2025: $24.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,213 · Food and Beverage: $265.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,213.00 |
| Food and Beverage | $264.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $4,237.95 | 2023-2025 | Skyclarys, Spinraza |
| Emd Serono, INC. | $271.10 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $140.65 | 2022-2023 | Ultomiris |
| Argenx US, INC. | $121.81 | 2023 | Vyvgart |
| Biohaven Pharmaceutical Holding Company LTD. | $66.21 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $26.33 | 2022 | |
| Xeris Pharmaceuticals, INC. | $18.62 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Carberry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.